Last reviewed · How we verify

NCT05142904: RABITO

Radiofrequency Ablation Versus I-131 for Solitary Autonomous Thyroid Nodules

Terminated Phase 3 Last updated 17 July 2025
What this trial tests

Phase 3 trial testing Radiofrequency ablation in Thyroid Nodule, Toxic or With Hyperthyroidism in 40 participants. Terminated before completion.

Timeline
17 November 2021
Primary endpoint
1 November 2024
1 November 2024

Quick facts

Lead sponsorRijnstate Hospital
PhasePhase 3
StatusTerminated
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment40
Start date17 November 2021
Primary completion1 November 2024
Estimated completion1 November 2024
Sites14 locations across Netherlands

Drugs / interventions tested

Conditions studied

Sponsor

Rijnstate Hospital

Who can join

18 and older, any sex, with Thyroid Nodule, Toxic or With Hyperthyroidism or Autonomous Thyroid Function. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to compare treatment of hyperthyroidism with radiofrequency ablation or I-131 for solitary autonomous thyroid nodules.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Radiofrequency ablation

Trials testing the same drug.

Other Rijnstate Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05142904.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing